ALHC

SEC source: 0001209191-22-059508 · doc4.xml · nonDerivative · entry 1

KAO JOHN E · CIK 0001222028 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,724,200

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $13.00 to $13.38. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

F3 · ownership.nature: Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

SEC source: 0001209191-22-062017 · doc4.xml · nonDerivative · entry 2

Maroney Dawn Christine · CIK 0001850397 · President, Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,975,692

F2 · kind: Represents bona fide gifts to family members.

SEC source: 0001209191-22-056201 · doc4.xml · nonDerivative · entry 1

McCarthy Margaret M · CIK 0001485980 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 61,318

F1 · kind: Represents 1,429 restricted stock units, each restricted stock unit representing the right to receive one share of Common Stock of the Company, that will vest 100% on the one-year anniversary of the grant date, subject to the reporting person's continued service to the Company as of the applicable vesting date.

SEC source: 0001209191-22-056195 · doc4.xml · derivative · entry 2

KONOWIECKI JOSEPH S · CIK 0001209523 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,817

Underlying: Common Stock · 35,817 shares

Expires 2032-11-07

F2 · derivative.exercise_date: Options vest 25% on each of the first four anniversaries of the grant date, subject to the reporting person's continued service to the Company as of the applicable vesting date.

SEC source: 0001209191-22-056195 · doc4.xml · nonDerivative · entry 1

KONOWIECKI JOSEPH S · CIK 0001209523 · Director · Chairman of the Board

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 918,903

F1 · kind: Represents 53,906 restricted stock units, each restricted stock unit representing the right to receive one share of Common Stock of the Company, that will vest 25% on each of the first four anniversaries of the grant date, subject to the reporting person's continued service to the Company. The reporting person has elected to defer receipt of the underlying shares for three years (or, if earlier, upon separation of service or a change of control of the Company).

SEC source: 0001209191-22-055290 · doc4.xml · nonDerivative · entry 1

Freeman Robert Thomas · CIK 0001850414 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 544,529

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $13.10 to $13.38. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

F3 · ownership.nature: Represents securities held by FCO Holdings LLC, a limited liability company owned by FCO Holdings Trust One, an irrevocable trust of which Mr. Freeman is an indirect beneficiary.

SEC source: 0001209191-22-055299 · doc4.xml · nonDerivative · entry 1

Kumar Dinesh M. · CIK 0001850439 · Chief Med & Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,147,226

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $13.09 to $13.82. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-22-055287 · doc4.xml · nonDerivative · entry 1

KAO JOHN E · CIK 0001222028 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,749,200

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $13.08 to $13.38. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

F3 · ownership.nature: Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

SEC source: 0001209191-22-054806 · doc4.xml · nonDerivative · entry 1

Freeman Robert Thomas · CIK 0001850414 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 568,529

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $13.00 to $13.25. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

F3 · ownership.nature: Represents securities held by FCO Holdings LLC, a limited liability company owned by FCO Holdings Trust One, an irrevocable trust of which Mr. Freeman is an indirect beneficiary.

SEC source: 0001209191-22-054807 · doc4.xml · nonDerivative · entry 1

Kumar Dinesh M. · CIK 0001850439 · Chief Med & Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,177,226

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $13.00 to $13.08. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-22-054805 · doc4.xml · nonDerivative · entry 1

KAO JOHN E · CIK 0001222028 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,774,200

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $13.00 to $13.25. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

F3 · ownership.nature: Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

SEC source: 0001209191-22-052900 · doc4.xml · nonDerivative · entry 1

Kumar Dinesh M. · CIK 0001850439 · Chief Med & Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,187,226

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $11.69 to $12.28. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

SEC source: 0000950142-22-002772 · es220287787_4-alhcwp2.xml · nonDerivative · entry 1

Warburg Pincus Partners GP LLC · CIK 0001621224 · Director · 10% owner

WARBURG PINCUS & CO. · CIK 0000929408 · Director · 10% owner

Warburg Pincus Partners II Holdings, L.P. · CIK 0001894855 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 17,922,779

F1 · kind: Represents 1,316,565 shares of Common Stock sold by Warburg Pincus Private Equity XII, L.P., a Delaware limited partnership ("WP XII"), 264,147 shares of Common Stock sold by Warburg Pincus Private Equity XII-B, L.P., a Delaware limited partnership ("WP XII-B"), 37,998 shares of Common Stock sold by Warburg Pincus Private Equity XII-D, L.P., a Delaware limited partnership ("WP XII-D"), and 216,869 shares of Common Stock sold by Warburg Pincus Private Equity XII-E, L.P., a Delaware limited partnership ("WP XII-E"), 71,029 shares of Common Stock sold by WP XII Partners, L.P., a Delaware limited partnership ("WP XII Partners"), and 137,398 shares of Common Stock sold by Warburg Pincus XII Partners, L.P., a Delaware limited partnership ("Warburg Pincus XII Partners") pursuant to a registered block trade that closed on September 20, 2022 (the "Transaction"), at a price of $14.61.

F2 · ownership.nature: Reflects securities held directly by WP XII, WP XII-B, WP XII-D, WP XII-E, WP XII Partners, and Warburg Pincus XII Partners (together with WP XII, WP XII-B, WP XII-D, WP XII-E, and WP XII Partners, the "WP XII Funds") following the closing of the Transaction. Warburg Pincus XII, L.P., a Delaware limited partnership ("WP XII GP"), is the general partner of the WP XII Funds. WP Global LLC, a Delaware limited liability company ("WP Global"), is the general partner of WP XII GP. Warburg Pincus Partners II, L.P., a Delaware limited partnership ("WPP II"), is the managing member of WP Global. Warburg Pincus Partners II Holdings, L.P., a Delaware limited partnership ("WPP II Holdings"), is a limited partner of WPP II. Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WPP II and WPP II Holdings. Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WPP GP. (Cont'd in FN3)

F3 · ownership.nature: (Cont'd from FN2) Warburg Pincus LLC, a New York limited liability company ("WP LLC") is a registered investment adviser and the manager of the WP XII Funds. Investment and voting decisions with respect to the shares held by the WP XII Funds are made by a committee comprised of three or more individuals and all members of such committee disclaim beneficial ownership of the shares.

SEC source: 0000950142-22-002764 · es220287788_4-alhc1.xml · nonDerivative · entry 1

GENERAL ATLANTIC, L.P. · CIK 0001017645 · Director · 10% owner

GENERAL ATLANTIC GENPAR, L.P. · CIK 0001467926 · Director · 10% owner

General Atlantic Partners 95, L.P. · CIK 0001606259 · Director · 10% owner

GAP COINVESTMENTS III, LLC · CIK 0001282203 · Director · 10% owner

GAP COINVESTMENTS IV, LLC · CIK 0001282372 · Director · 10% owner

GAP Coinvestments V, LLC · CIK 0001793941 · Director · 10% owner

GAPCO GMBH & CO KG · CIK 0001187388 · Director · 10% owner

GAPCO MANAGEMENT GMBH · CIK 0001187390 · Director · 10% owner

GAP Coinvestments CDA, L.P. · CIK 0001356474 · Director · 10% owner

General Atlantic (SPV) GP, LLC · CIK 0001793940 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 60,993,323

F1 · kind: The shares of Common Stock were sold by General Atlantic (ALN HLTH), L.P., a Delaware limited partnership ("GA ALN"), pursuant to a registered block trade that closed on September 20, 2022 (the "Transaction"), at a price of $14.61.

F2 · ownership.nature: Reflects securities held directly by GA ALN following the closing of the Transaction. The limited partners of GA ALN are the following investment funds (the "GA Funds"): General Atlantic Partners 95, L.P., a Delaware limited partnership ("GAP 95"), GAP Coinvestments CDA, L.P., a Delaware limited partnership ("GAPCO CDA"), GAP Coinvestments III, LLC, a Delaware limited liability company ("GAPCO III"), GAP Coinvestments IV, LLC, a Delaware limited liability company ("GAPCO IV"), GAP Coinvestments V, LLC, a Delaware limited liability company ("GAPCO V") and GAPCO GmbH & Co. KG, a German partnership ("GAPCO KG"). (Cont'd in FN3)

F3 · ownership.nature: (Cont'd from FN2) General Atlantic GenPar, L.P., a Delaware limited partnership ("GA GenPar"), is the general partner of GAP 95. General Atlantic (SPV) GP, LLC, a Delaware limited liability company ("GA SPV"), is the general partner of GA ALN. General Atlantic, L.P., a Delaware limited partnership ("GA LP") is the general partner of GA GenPar and GAPCO CDA, the managing member of GAPCO III, GAPCO IV and GAPCO V, and the sole member of GA SPV. GA LP is controlled by the Management Committee of GASC MGP, LLC (the "Management Committee"). GAPCO Management GmbH, a German company ("GAPCO Management"), is the general partner of GAPCO KG. There are nine members of the Management Committee. Each of the members of the Management Committee disclaims ownership of the shares except to the extent he has a pecuniary interest therein.

SEC source: 0000950142-22-002771 · es220287786_4-alhcwp1.xml · nonDerivative · entry 1

WARBURG PINCUS LLC · CIK 0001162870 · Director · 10% owner

Warburg Pincus Private Equity XII, L.P. · CIK 0001658396 · Director · 10% owner

Warburg Pincus Private Equity XII-B, L.P. · CIK 0001658398 · Director · 10% owner

Warburg Pincus Private Equity XII-D, L.P. · CIK 0001658400 · Director · 10% owner

Warburg Pincus Private Equity XII-E, L.P. · CIK 0001658404 · Director · 10% owner

WP XII Partners, L.P. · CIK 0001658414 · Director · 10% owner

Warburg Pincus XII Partners, L.P. · CIK 0001658412 · Director · 10% owner

WARBURG PINCUS XII, L.P. · CIK 0001672765 · Director · 10% owner

WP Global LLC · CIK 0001540385 · Director · 10% owner

Warburg Pincus Partners II, L.P. · CIK 0001658787 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 17,922,779

F1 · kind: Represents 1,316,565 shares of Common Stock sold by Warburg Pincus Private Equity XII, L.P., a Delaware limited partnership ("WP XII"), 264,147 shares of Common Stock sold by Warburg Pincus Private Equity XII-B, L.P., a Delaware limited partnership ("WP XII-B"), 37,998 shares of Common Stock sold by Warburg Pincus Private Equity XII-D, L.P., a Delaware limited partnership ("WP XII-D"), and 216,869 shares of Common Stock sold by Warburg Pincus Private Equity XII-E, L.P., a Delaware limited partnership ("WP XII-E"), 71,029 shares of Common Stock sold by WP XII Partners, L.P., a Delaware limited partnership ("WP XII Partners"), and 137,398 shares of Common Stock sold by Warburg Pincus XII Partners, L.P., a Delaware limited partnership ("Warburg Pincus XII Partners") pursuant to a registered block trade that closed on September 20, 2022 (the "Transaction"), at a price of $14.61.

F2 · ownership.nature: Reflects securities held directly by WP XII, WP XII-B, WP XII-D, WP XII-E, WP XII Partners, and Warburg Pincus XII Partners (together with WP XII, WP XII-B, WP XII-D, WP XII-E, and WP XII Partners, the "WP XII Funds") following the closing of the Transaction. Warburg Pincus XII, L.P., a Delaware limited partnership ("WP XII GP"), is the general partner of the WP XII Funds. WP Global LLC, a Delaware limited liability company ("WP Global"), is the general partner of WP XII GP. Warburg Pincus Partners II, L.P., a Delaware limited partnership ("WPP II"), is the managing member of WP Global. Warburg Pincus Partners II Holdings, L.P., a Delaware limited partnership ("WPP II Holdings"), is a limited partner of WPP II. Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WPP II and WPP II Holdings. Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WPP GP. (Cont'd in FN3)

F3 · ownership.nature: (Cont'd from FN2) Warburg Pincus LLC, a New York limited liability company ("WP LLC") is a registered investment adviser and the manager of the WP XII Funds. Investment and voting decisions with respect to the shares held by the WP XII Funds are made by a committee comprised of three or more individuals and all members of such committee disclaim beneficial ownership of the shares.

SEC source: 0000950142-22-002765 · es220287789_4-alhc2.xml · nonDerivative · entry 1

General Atlantic (ALN HLTH), L.P. · CIK 0001853603 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 60,993,323

F1 · kind: The shares of Common Stock were sold by General Atlantic (ALN HLTH), L.P., a Delaware limited partnership ("GA ALN"), pursuant to a registered block trade that closed on September 20, 2022 (the "Transaction"), at a price of $14.61.

F2 · ownership.nature: Reflects securities held directly by GA ALN following the closing of the Transaction. The limited partners of GA ALN are the following investment funds (the "GA Funds"): General Atlantic Partners 95, L.P., a Delaware limited partnership ("GAP 95"), GAP Coinvestments CDA, L.P., a Delaware limited partnership ("GAPCO CDA"), GAP Coinvestments III, LLC, a Delaware limited liability company ("GAPCO III"), GAP Coinvestments IV, LLC, a Delaware limited liability company ("GAPCO IV"), GAP Coinvestments V, LLC, a Delaware limited liability company ("GAPCO V") and GAPCO GmbH & Co. KG, a German partnership ("GAPCO KG"). (Cont'd in FN3)

F3 · ownership.nature: (Cont'd from FN2) General Atlantic GenPar, L.P., a Delaware limited partnership ("GA GenPar"), is the general partner of GAP 95. General Atlantic (SPV) GP, LLC, a Delaware limited liability company ("GA SPV"), is the general partner of GA ALN. General Atlantic, L.P., a Delaware limited partnership ("GA LP") is the general partner of GA GenPar and GAPCO CDA, the managing member of GAPCO III, GAPCO IV and GAPCO V, and the sole member of GA SPV. GA LP is controlled by the Management Committee of GASC MGP, LLC (the "Management Committee"). GAPCO Management GmbH, a German company ("GAPCO Management"), is the general partner of GAPCO KG. There are nine members of the Management Committee. Each of the members of the Management Committee disclaims ownership of the shares except to the extent he has a pecuniary interest therein.

SEC source: 0001209191-22-049770 · doc4.xml · nonDerivative · entry 1

Cross Richard A. · CIK 0001879095 · SVP, General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,686

F1 · kind: Represents 102,759 restricted stock units, each restricted stock unit representing the right to receive one share of Common Stock of the Company, that will vest 50% on each of the third and fourth anniversaries of the grant date, subject to the reporting person's continued service to the Company.

SEC source: 0001209191-22-049768 · doc4.xml · nonDerivative · entry 1

Maroney Dawn Christine · CIK 0001850397 · President, Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,981,142

F1 · kind: Represents 431,323 restricted stock units, each restricted stock unit representing the right to receive one share of Common Stock of the Company, that will vest 50% on each of the third and fourth anniversaries of the grant date, subject to the reporting person's continued service to the Company.

SEC source: 0001209191-22-049767 · doc4.xml · nonDerivative · entry 1

Freeman Robert Thomas · CIK 0001850414 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 731,448

F1 · kind: Represents 319,179 restricted stock units, each restricted stock unit representing the right to receive one share of Common Stock of the Company, that will vest 50% on each of the third and fourth anniversaries of the grant date, subject to the reporting person's continued service to the Company.

SEC source: 0001209191-22-049769 · doc4.xml · nonDerivative · entry 1

Kumar Dinesh M. · CIK 0001850439 · Chief Med & Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,207,226

F1 · kind: Represents 280,360 restricted stock units, each restricted stock unit representing the right to receive one share of Common Stock of the Company, that will vest 50% on each of the third and fourth anniversaries of the grant date, subject to the reporting person's continued service to the Company.

SEC source: 0001209191-22-049765 · doc4.xml · nonDerivative · entry 1

KAO JOHN E · CIK 0001222028 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,420,380

F1 · kind: Represents 1,639,027 restricted stock units, each restricted stock unit representing the right to receive one share of Common Stock of the Company, that will vest 50% on each of the third and fourth anniversaries of the grant date, subject to the reporting person's continued service to the Company.

SEC source: 0001209191-22-049374 · doc4.xml · nonDerivative · entry 1

Maroney Dawn Christine · CIK 0001850397 · President, Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,549,819

F1 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $16.60 to $16.63. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-22-062017 · doc4.xml · nonDerivative · entry 1

Maroney Dawn Christine · CIK 0001850397 · President, Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,549,369

F1 · kind: Represents a bona fide gift to a nonprofit organization.

SEC source: 0001209191-22-049371 · doc4.xml · nonDerivative · entry 1

Kumar Dinesh M. · CIK 0001850439 · Chief Med & Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 926,866

F1 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $16.00 to $16.2150. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-22-048493 · doc4.xml · nonDerivative · entry 1

Maroney Dawn Christine · CIK 0001850397 · President, Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,560,069

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $14.30 to $14.81. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-22-048482 · doc4.xml · nonDerivative · entry 1

Freeman Robert Thomas · CIK 0001850414 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 592,529

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $14.30 to $14.82. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

F3 · ownership.nature: Represents securities held by FCO Holdings LLC, a limited liability company owned by FCO Holdings Trust One, an irrevocable trust of which Mr. Freeman is an indirect beneficiary.

SEC source: 0001209191-22-048487 · doc4.xml · nonDerivative · entry 1

Kumar Dinesh M. · CIK 0001850439 · Chief Med & Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 976,866

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $14.31 to $14.84. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-22-048485 · doc4.xml · nonDerivative · entry 1

KAO JOHN E · CIK 0001222028 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,799,200

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $14.3050 to $14.84. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

F3 · ownership.nature: Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

SEC source: 0000950142-22-002596 · es220281398_4-alhcwp2.xml · nonDerivative · entry 1

Warburg Pincus Partners GP LLC · CIK 0001621224 · Director · 10% owner

WARBURG PINCUS & CO. · CIK 0000929408 · Director · 10% owner

Warburg Pincus Partners II Holdings, L.P. · CIK 0001894855 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 19,966,785

F1 · kind: Represents 439,283 shares of Common Stock sold by Warburg Pincus Private Equity XII, L.P., a Delaware limited partnership ("WP XII"), 88,135 shares of Common Stock sold by Warburg Pincus Private Equity XII-B, L.P., a Delaware limited partnership ("WP XII-B"), 12,678 shares of Common Stock sold by Warburg Pincus Private Equity XII-D, L.P., a Delaware limited partnership ("WP XII-D"), and 72,360 shares of Common Stock sold by Warburg Pincus Private Equity XII-E, L.P., a Delaware limited partnership ("WP XII-E"), 23,700 shares of Common Stock sold by WP XII Partners, L.P., a Delaware limited partnership ("WP XII Partners"), and 45,844 shares of Common Stock sold by Warburg Pincus XII Partners, L.P., a Delaware limited partnership ("Warburg Pincus XII Partners").

F2 · ownership.nature: Reflects securities held directly by WP XII, WP XII-B, WP XII-D, WP XII-E, WP XII Partners, and Warburg Pincus XII Partners (together with WP XII, WP XII-B, WP XII-D, WP XII-E, and WP XII Partners, the "WP XII Funds"). Warburg Pincus XII, L.P., a Delaware limited partnership ("WP XII GP"), is the general partner of the WP XII Funds. WP Global LLC, a Delaware limited liability company ("WP Global"), is the general partner of WP XII GP. Warburg Pincus Partners II, L.P., a Delaware limited partnership ("WPP II"), is the managing member of WP Global. Warburg Pincus Partners II Holdings, L.P., a Delaware limited partnership ("WPP II Holdings"), is a limited partner of WPP II. Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WPP II and WPP II Holdings. Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WPP GP. (Cont'd in FN3)

F3 · ownership.nature: (Cont'd from FN2) Warburg Pincus LLC, a New York limited liability company ("WP LLC") is a registered investment adviser and the manager of the WP XII Funds. Investment and voting decisions with respect to the shares held by the WP XII Funds are made by a committee comprised of three or more individuals and all members of such committee disclaim beneficial ownership of the shares.

SEC source: 0000950142-22-002594 · es220281397_4-alhcwp1.xml · nonDerivative · entry 1

WARBURG PINCUS LLC · CIK 0001162870 · Director · 10% owner

Warburg Pincus Private Equity XII, L.P. · CIK 0001658396 · Director · 10% owner

Warburg Pincus Private Equity XII-B, L.P. · CIK 0001658398 · Director · 10% owner

Warburg Pincus Private Equity XII-D, L.P. · CIK 0001658400 · Director · 10% owner

Warburg Pincus Private Equity XII-E, L.P. · CIK 0001658404 · Director · 10% owner

WP XII Partners, L.P. · CIK 0001658414 · Director · 10% owner

Warburg Pincus XII Partners, L.P. · CIK 0001658412 · Director · 10% owner

WARBURG PINCUS XII, L.P. · CIK 0001672765 · Director · 10% owner

WP Global LLC · CIK 0001540385 · Director · 10% owner

Warburg Pincus Partners II, L.P. · CIK 0001658787 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 19,966,785

F1 · kind: Represents 439,283 shares of Common Stock sold by Warburg Pincus Private Equity XII, L.P., a Delaware limited partnership ("WP XII"), 88,135 shares of Common Stock sold by Warburg Pincus Private Equity XII-B, L.P., a Delaware limited partnership ("WP XII-B"), 12,678 shares of Common Stock sold by Warburg Pincus Private Equity XII-D, L.P., a Delaware limited partnership ("WP XII-D"), and 72,360 shares of Common Stock sold by Warburg Pincus Private Equity XII-E, L.P., a Delaware limited partnership ("WP XII-E"), 23,700 shares of Common Stock sold by WP XII Partners, L.P., a Delaware limited partnership ("WP XII Partners"), and 45,844 shares of Common Stock sold by Warburg Pincus XII Partners, L.P., a Delaware limited partnership ("Warburg Pincus XII Partners").

F2 · ownership.nature: Reflects securities held directly by WP XII, WP XII-B, WP XII-D, WP XII-E, WP XII Partners, and Warburg Pincus XII Partners (together with WP XII, WP XII-B, WP XII-D, WP XII-E, and WP XII Partners, the "WP XII Funds"). Warburg Pincus XII, L.P., a Delaware limited partnership ("WP XII GP"), is the general partner of the WP XII Funds. WP Global LLC, a Delaware limited liability company ("WP Global"), is the general partner of WP XII GP. Warburg Pincus Partners II, L.P., a Delaware limited partnership ("WPP II"), is the managing member of WP Global. Warburg Pincus Partners II Holdings, L.P., a Delaware limited partnership ("WPP II Holdings"), is a limited partner of WPP II. Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WPP II and WPP II Holdings. Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WPP GP. (Cont'd in FN3)

F3 · ownership.nature: (Cont'd from FN2) Warburg Pincus LLC, a New York limited liability company ("WP LLC") is a registered investment adviser and the manager of the WP XII Funds. Investment and voting decisions with respect to the shares held by the WP XII Funds are made by a committee comprised of three or more individuals and all members of such committee disclaim beneficial ownership of the shares.

SEC source: 0001209191-22-047375 · doc4.xml · nonDerivative · entry 2

Maroney Dawn Christine · CIK 0001850397 · President, Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,580,069

F2 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $15.90 to $16.0640.

SEC source: 0001209191-22-047482 · doc4.xml · nonDerivative · entry 1

Kumar Dinesh M. · CIK 0001850439 · Chief Med & Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,006,866

F1 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $16.00 to $16.0550. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

SEC source: 0001209191-22-047375 · doc4.xml · nonDerivative · entry 1

Maroney Dawn Christine · CIK 0001850397 · President, Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,593,782

F1 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $15.90 to $15.9150. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (1) and (2) to this Form 4.

SEC source: 0001209191-22-046442 · doc4.xml · nonDerivative · entry 1

Maroney Dawn Christine · CIK 0001850397 · President, Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,610,069

SEC source: 0001209191-22-045615 · doc4.xml · nonDerivative · entry 1

KAO JOHN E · CIK 0001222028 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,849,200

F1 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $15.95 to $16.67. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range.

F2 · ownership.nature: Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

SEC source: 0000950142-22-002541 · es220279638_4-alhcwp2.xml · nonDerivative · entry 1

Warburg Pincus Partners GP LLC · CIK 0001621224 · Director · 10% owner

WARBURG PINCUS & CO. · CIK 0000929408 · Director · 10% owner

Warburg Pincus Partners II Holdings, L.P. · CIK 0001894855 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 20,648,785

F1 · kind: Represents 1,365,513 shares of Common Stock sold by Warburg Pincus Private Equity XII, L.P., a Delaware limited partnership ("WP XII"), 273,968 shares of Common Stock sold by Warburg Pincus Private Equity XII-B, L.P., a Delaware limited partnership ("WP XII-B"), 39,411 shares of Common Stock sold by Warburg Pincus Private Equity XII-D, L.P., a Delaware limited partnership ("WP XII-D"), and 224,932 shares of Common Stock sold by Warburg Pincus Private Equity XII-E, L.P., a Delaware limited partnership ("WP XII-E"), 73,670 shares of Common Stock sold by WP XII Partners, L.P., a Delaware limited partnership ("WP XII Partners"), and 142,506 shares of Common Stock sold by Warburg Pincus XII Partners, L.P., a Delaware limited partnership ("Warburg Pincus XII Partners").

F2 · ownership.nature: Reflects securities held directly by WP XII, WP XII-B, WP XII-D, WP XII-E, WP XII Partners, and Warburg Pincus XII Partners (together with WP XII, WP XII-B, WP XII-D, WP XII-E, and WP XII Partners, the "WP XII Funds"). Warburg Pincus XII, L.P., a Delaware limited partnership ("WP XII GP"), is the general partner of the WP XII Funds. WP Global LLC, a Delaware limited liability company ("WP Global"), is the general partner of WP XII GP. Warburg Pincus Partners II, L.P., a Delaware limited partnership ("WPP II"), is the managing member of WP Global. Warburg Pincus Partners II Holdings, L.P., a Delaware limited partnership ("WPP II Holdings"), is a limited partner of WPP II. Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WPP II and WPP II Holdings. Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WPP GP. (Cont'd in FN3)

F3 · ownership.nature: (Cont'd from FN2) Warburg Pincus LLC, a New York limited liability company ("WP LLC") is a registered investment adviser and the manager of the WP XII Funds. Investment and voting decisions with respect to the shares held by the WP XII Funds are made by a committee comprised of three or more individuals and all members of such committee disclaim beneficial ownership of the shares.

SEC source: 0000950142-22-002540 · es220279365_4-alhcwp1.xml · nonDerivative · entry 1

WARBURG PINCUS LLC · CIK 0001162870 · Director · 10% owner

Warburg Pincus Private Equity XII, L.P. · CIK 0001658396 · Director · 10% owner

Warburg Pincus Private Equity XII-B, L.P. · CIK 0001658398 · Director · 10% owner

Warburg Pincus Private Equity XII-D, L.P. · CIK 0001658400 · Director · 10% owner

Warburg Pincus Private Equity XII-E, L.P. · CIK 0001658404 · Director · 10% owner

WP XII Partners, L.P. · CIK 0001658414 · Director · 10% owner

Warburg Pincus XII Partners, L.P. · CIK 0001658412 · Director · 10% owner

WARBURG PINCUS XII, L.P. · CIK 0001672765 · Director · 10% owner

WP Global LLC · CIK 0001540385 · Director · 10% owner

Warburg Pincus Partners II, L.P. · CIK 0001658787 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 20,648,785

F1 · kind: Represents 1,365,513 shares of Common Stock sold by Warburg Pincus Private Equity XII, L.P., a Delaware limited partnership ("WP XII"), 273,968 shares of Common Stock sold by Warburg Pincus Private Equity XII-B, L.P., a Delaware limited partnership ("WP XII-B"), 39,411 shares of Common Stock sold by Warburg Pincus Private Equity XII-D, L.P., a Delaware limited partnership ("WP XII-D"), and 224,932 shares of Common Stock sold by Warburg Pincus Private Equity XII-E, L.P., a Delaware limited partnership ("WP XII-E"), 73,670 shares of Common Stock sold by WP XII Partners, L.P., a Delaware limited partnership ("WP XII Partners"), and 142,506 shares of Common Stock sold by Warburg Pincus XII Partners, L.P., a Delaware limited partnership ("Warburg Pincus XII Partners").

F2 · ownership.nature: Reflects securities held directly by WP XII, WP XII-B, WP XII-D, WP XII-E, WP XII Partners, and Warburg Pincus XII Partners (together with WP XII, WP XII-B, WP XII-D, WP XII-E, and WP XII Partners, the "WP XII Funds"). Warburg Pincus XII, L.P., a Delaware limited partnership ("WP XII GP"), is the general partner of the WP XII Funds. WP Global LLC, a Delaware limited liability company ("WP Global"), is the general partner of WP XII GP. Warburg Pincus Partners II, L.P., a Delaware limited partnership ("WPP II"), is the managing member of WP Global. Warburg Pincus Partners II Holdings, L.P., a Delaware limited partnership ("WPP II Holdings"), is a limited partner of WPP II. Warburg Pincus Partners GP LLC, a Delaware limited liability company ("WPP GP"), is the general partner of WPP II and WPP II Holdings. Warburg Pincus & Co., a New York general partnership ("WP"), is the managing member of WPP GP. (Cont'd in FN3)

F3 · ownership.nature: (Cont'd from FN2) Warburg Pincus LLC, a New York limited liability company ("WP LLC") is a registered investment adviser and the manager of the WP XII Funds. Investment and voting decisions with respect to the shares held by the WP XII Funds are made by a committee comprised of three or more individuals and all members of such committee disclaim beneficial ownership of the shares.

SEC source: 0000950142-22-002442 · es220277794_4-alhc1.xml · nonDerivative · entry 1

GENERAL ATLANTIC, L.P. · CIK 0001017645 · Director · 10% owner

GENERAL ATLANTIC GENPAR, L.P. · CIK 0001467926 · Director · 10% owner

General Atlantic Partners 95, L.P. · CIK 0001606259 · Director · 10% owner

GAP COINVESTMENTS III, LLC · CIK 0001282203 · Director · 10% owner

GAP COINVESTMENTS IV, LLC · CIK 0001282372 · Director · 10% owner

GAP Coinvestments V, LLC · CIK 0001793941 · Director · 10% owner

GAPCO GMBH & CO KG · CIK 0001187388 · Director · 10% owner

GAPCO MANAGEMENT GMBH · CIK 0001187390 · Director · 10% owner

GAP Coinvestments CDA, L.P. · CIK 0001356474 · Director · 10% owner

General Atlantic (SPV) GP, LLC · CIK 0001793940 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 67,949,317

F1 · ownership.nature: Reflects securities held directly by General Atlantic (ALN HLTH), L.P., a Delaware limited partnership ("GA ALN"). The limited partners of GA ALN are the following investment funds (the "GA Funds"): General Atlantic Partners 95, L.P., a Delaware limited partnership ("GAP 95"), GAP Coinvestments CDA, L.P., a Delaware limited partnership ("GAPCO CDA"), GAP Coinvestments III, LLC, a Delaware limited liability company ("GAPCO III"), GAP Coinvestments IV, LLC, a Delaware limited liability company ("GAPCO IV"), GAP Coinvestments V, LLC, a Delaware limited liability company ("GAPCO V") and GAPCO GmbH & Co. KG, a German partnership ("GAPCO KG"). (Cont'd in FN2)

F2 · ownership.nature: (Cont'd from FN1) General Atlantic GenPar, L.P., a Delaware limited partnership ("GA GenPar"), is the general partner of GAP 95. General Atlantic (SPV) GP, LLC, a Delaware limited liability company ("GA SPV"), is the general partner of GA ALN. General Atlantic, L.P., a Delaware limited partnership ("GA LP") is the general partner of GA GenPar and GAPCO CDA, the managing member of GAPCO III, GAPCO IV and GAPCO V, and the sole member of GA SPV. GA LP is controlled by the Management Committee of GASC MGP, LLC (the "Management Committee"). GAPCO Management GmbH, a German company ("GAPCO Management"), is the general partner of GAPCO KG. There are nine members of the Management Committee. Each of the members of the Management Committee disclaims ownership of the shares except to the extent he has a pecuniary interest therein.

SEC source: 0000950142-22-002443 · es220277798_4-alhc2.xml · nonDerivative · entry 1

General Atlantic (ALN HLTH), L.P. · CIK 0001853603 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 67,949,317

F1 · ownership.nature: Reflects securities held directly by General Atlantic (ALN HLTH), L.P., a Delaware limited partnership ("GA ALN"). The limited partners of GA ALN are the following investment funds (the "GA Funds"): General Atlantic Partners 95, L.P., a Delaware limited partnership ("GAP 95"), GAP Coinvestments CDA, L.P., a Delaware limited partnership ("GAPCO CDA"), GAP Coinvestments III, LLC, a Delaware limited liability company ("GAPCO III"), GAP Coinvestments IV, LLC, a Delaware limited liability company ("GAPCO IV"), GAP Coinvestments V, LLC, a Delaware limited liability company ("GAPCO V") and GAPCO GmbH & Co. KG, a German partnership ("GAPCO KG"). (Cont'd in FN2)

F2 · ownership.nature: (Cont'd from FN1) General Atlantic GenPar, L.P., a Delaware limited partnership ("GA GenPar"), is the general partner of GAP 95. General Atlantic (SPV) GP, LLC, a Delaware limited liability company ("GA SPV"), is the general partner of GA ALN. General Atlantic, L.P., a Delaware limited partnership ("GA LP") is the general partner of GA GenPar and GAPCO CDA, the managing member of GAPCO III, GAPCO IV and GAPCO V, and the sole member of GA SPV. GA LP is controlled by the Management Committee of GASC MGP, LLC (the "Management Committee"). GAPCO Management GmbH, a German company ("GAPCO Management"), is the general partner of GAPCO KG. There are nine members of the Management Committee. Each of the members of the Management Committee disclaims ownership of the shares except to the extent he has a pecuniary interest therein.

SEC source: 0001209191-22-045021 · doc4.xml · nonDerivative · entry 1

MARGOLIS JEFFREY H · CIK 0001105688 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 425,533

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · ownership.nature: Represents securities held by the Margolis Family trust 12/23/98, of which Mr. Margolis is the trustee.

SEC source: 0001209191-22-045008 · doc4.xml · nonDerivative · entry 2

Freeman Robert Thomas · CIK 0001850414 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 616,529

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F4 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $19.00 to $19.06.

F3 · ownership.nature: Represents securities held by FCO Holdings LLC, a limited liability company owned by FCO Holdings Trust One, an irrevocable trust of which Mr. Freeman is an indirect beneficiary.

SEC source: 0001209191-22-045008 · doc4.xml · nonDerivative · entry 1

Freeman Robert Thomas · CIK 0001850414 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 619,442

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $18.00 to $18.99. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (2) and (4) to this Form 4.

F3 · ownership.nature: Represents securities held by FCO Holdings LLC, a limited liability company owned by FCO Holdings Trust One, an irrevocable trust of which Mr. Freeman is an indirect beneficiary.

SEC source: 0001209191-22-045016 · doc4.xml · nonDerivative · entry 2

Kumar Dinesh M. · CIK 0001850439 · Chief Med & Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,056,866

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F3 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $19.00 to $19.13.

SEC source: 0001209191-22-045016 · doc4.xml · nonDerivative · entry 1

Kumar Dinesh M. · CIK 0001850439 · Chief Med & Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,059,397

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $18.00 to $18.99. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (2) and (3) to this Form 4.

SEC source: 0001209191-22-045003 · doc4.xml · nonDerivative · entry 2

KAO JOHN E · CIK 0001222028 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,349,200

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F4 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $19.00 to $19.14.

F3 · ownership.nature: Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

SEC source: 0001209191-22-045003 · doc4.xml · nonDerivative · entry 1

KAO JOHN E · CIK 0001222028 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,353,203

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · price: The reported price in column 4 is a weighted-average price. Shares were sold in multiple transactions at a per share price ranging from $18.00 to $18.99. The reporting person undertakes to provide to Alignment Healthcare, Inc., any security holder of Alignment Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes (2) and (4) to this Form 4.

F3 · ownership.nature: Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

SEC source: 0001209191-22-044009 · doc4.xml · nonDerivative · entry 2

KAO JOHN E · CIK 0001222028 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 3,415,391

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · ownership.nature: Represents securities held by JEK Trust, dated February 8, 2021, of which Mr. Kao is the trustee.

SEC source: 0001209191-22-044011 · doc4.xml · nonDerivative · entry 1

Maroney Dawn Christine · CIK 0001850397 · President, Markets

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,611,859

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

SEC source: 0001209191-22-044010 · doc4.xml · nonDerivative · entry 1

Freeman Robert Thomas · CIK 0001850414 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 659,939

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.

F2 · ownership.nature: Represents securities held by FCO Holdings LLC, a limited liability company owned by FCO Holdings Trust One, an irrevocable trust of which Mr. Freeman is an indirect beneficiary.

SEC source: 0001209191-22-044012 · doc4.xml · nonDerivative · entry 1

Kumar Dinesh M. · CIK 0001850439 · Chief Med & Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,100,970

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person.